ZIM
AVIR icon

Zacks Investment Management’s Atea Pharmaceuticals AVIR Stock Holding History

Zacks Investment Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,966
Closed -$46.8K – 661
2024
Q4 		$46.8K Sell
13,966
-9,974
-42% -$33.1K ﹤0.01% 658
2024
Q3 		$80.2K Buy
+23,940
New +$86.8K ﹤0.01% 666

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Zacks Investment Management's AVIR Position: Q1 2025 in Review

Zacks Investment Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2025, closing a stake of 13,966 shares — an estimated $46.8K sold.

Zacks Investment Management first reported a position in AVIR in Q3 2024 and held it in 2 quarters. The position peaked at $80.2K in Q3 2024. 103 funds tracked by Wall St. Rank hold AVIR as of Q1 2025.

  • Zacks Investment Management reported no remaining Atea Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Zacks Investment Management sold 13,966 Atea Pharmaceuticals shares in Q1 2025, an estimated $46.8K.
  • Zacks Investment Management first reported a position in Atea Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Zacks Investment Management's Atea Pharmaceuticals position peaked at $80.2K in Q3 2024.
  • 103 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2025.

Based on Zacks Investment Management's 13F filing for Q1 2025, filed 14 May 2025.